Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases
Assets expand immunology portfolio to include B-cell therapy and macrophage modulation - - IND-enabling studies are ongoing and will support the transition of these assets to clinical development in 20222023 - Aurinia Pharmaceuticals Inc. today announced the addition of two novel assets that will expand the Company’s rare autoimmune and kidney-related disease pipeline. “Over the past year, in anticipation of ...
Source: investingnews.com